The diagnostic anchor in this patient was a laboratory finding rather than a physical sign: a strongly positive test for antibodies against U1 ribonucleoprotein, a component of the spliceosome, the cellular machinery that edits messenger RNA before proteins are made. High-titer anti-U1-RNP antibodies are the serological hallmark of mixed connective tissue disease, a systemic autoimmune disorder first described by Gordon Sharp and colleagues in 1972 that combines features of systemic lupus erythematosus, polymyositis, and systemic sclerosis. The condition is rare, with an estimated prevalence of roughly 3 to 37 per 100,000 people, and it disproportionately affects women. Yet the antibodies themselves can appear in patients whose disease never develops the full overlap picture, which is precisely what made this case so difficult to classify.

On admission, the clinical picture was alarming. Proximal muscle strength was graded 4 out of 5 in the deltoids and biceps but only 2 out of 5 in the hip flexors and quadriceps, meaning the patient could not raise her legs off the bed. Cranial nerves were intact, and crucially there was no rash, no Gottron’s papules, no heliotrope discoloration around the eyes, and no Raynaud phenomenon, the finger-whitening response to cold that typically signals connective tissue disease. The absence of these cutaneous and vascular stigmata is one reason the diagnosis eluded clinicians for so long. Inflammatory myopathy usually announces itself in textbooks with visible clues; here the disease confined itself almost entirely to muscle.

The laboratory numbers told a dramatic story. Serum creatine kinase, the enzyme that leaks into blood when muscle fibers rupture, measured 9,883 IU/L, roughly 68 times the upper limit of normal. Aldolase, another muscle enzyme, was similarly elevated at 75.6 U/L against a reference ceiling of 10. Inflammatory markers were high, with C-reactive protein at 116 mg/L, and the erythrocyte sedimentation rate at 67 mm/h. The extractable nuclear antigen panel revealed anti-U1-RNP antibodies at 17.67 U/mL, well above the positivity threshold of 5.0, while antibodies to Sm, Scl-70, and SS-B/La were negative and anti-dsDNA was merely equivocal, arguing against florid lupus. A positive direct Coombs test was noted but, without reticulocytosis, elevated lactate dehydrogenase, or low haptoglobin, could not be taken as proof of autoimmune hemolysis.

Electrodiagnostic testing added an important nuance. Nerve conduction studies were normal, excluding a neuropathy, but needle electromyography across ten muscles showed small, short-duration motor unit potentials with early full recruitment and, tellingly, no fibrillations or positive sharp waves. That non-irritable pattern is more characteristic of a chronic or so-called burnt-out myopathy than of florid active inflammation. The authors interpret it as the electrophysiological fingerprint of the six-year disease course, upon which the massively elevated creatine kinase indicated a fresh, biochemically active wave of muscle injury. Magnetic resonance imaging of the thighs corroborated the picture, showing diffuse T2 and STIR hyperintensity in the quadriceps consistent with muscle edema and inflammation, with no bone marrow abnormality to suggest a dystrophy or malignancy.

Treatment began within days. The patient received intravenous pulse methylprednisolone, 500 mg daily for three consecutive days, a high-dose regimen chosen because of the severity of weakness and the rapidly progressive pharyngeal dysphagia with its attendant aspiration risk. The response was rapid and unequivocal. By day four, swallowing had improved enough to restore safe oral intake, upper limb strength had returned to 5 out of 5, and lower limb strength had climbed to 4 out of 5 on the Medical Research Council scale. She was transitioned to oral prednisolone at 1 mg per kilogram per day, with methotrexate added as a steroid-sparing immunosuppressant alongside folic acid supplementation. At four-week follow-up, creatine kinase had fallen to 560 IU/L, approaching normal, and the dysphagia had not recurred.

Why did swallowing fail so suddenly? The report explains that oropharyngeal dysphagia in inflammatory myopathy arises when inflammation strikes the striated pharyngeal musculature, specifically the cricopharyngeus and the inferior pharyngeal constrictors, the muscles that coordinate the pharyngeal phase of swallowing. This feature is well recognized in polymyositis and dermatomyositis but underreported in mixed connective tissue disease, and it carries a grim prognosis when missed, being associated with aspiration, malnutrition, and death. Its abrupt emergence here, progressing from solids to liquids in roughly ten days, underscores why clinicians are urged to treat new dysphagia in any patient with myopathy as an emergency demanding immediate immunosuppression.

The classification question is where the case becomes genuinely instructive. Four sets of criteria, those of Sharp, Alarcón-Segovia and Villareal, Kasukawa and Miyawaki, and Kahn and Appeboom, are used to define mixed connective tissue disease, and all four require high-titer anti-U1-RNP antibodies. But each also demands at least one classic overlap manifestation beyond myositis: Raynaud phenomenon, swollen fingers or hands, synovitis, acrosclerosis, or sclerodactyly. This patient had none of them. Formally, therefore, she did not fulfill any of the four classification systems, and the authors designate her condition an anti-U1-RNP-positive inflammatory myopathy rather than definite mixed connective tissue disease. Such patients are increasingly viewed as occupying an early, incomplete, or myositis-dominant point on the disease spectrum, and a proportion evolve to meet full criteria over time, which is why the authors emphasize longitudinal surveillance rather than a fixed label.

The case also carries a lesson about anemia. Hematological abnormalities affect an estimated 30 to 40 percent of mixed connective tissue disease patients, and Coombs-positive hemolytic anemia has been described, yet this patient’s refractory microcytic anemia was attributed to iron deficiency for years despite supplementation failing. In retrospect, the authors write, that persistent anemia was a missed opportunity for earlier systemic evaluation. They recommend that any patient with proximal muscle weakness and unexplained, supplementation-resistant anemia undergo an autoimmune workup, including an extractable nuclear antigen panel and myositis-specific antibodies, early rather than late.

The authors acknowledge limitations: no muscle biopsy was performed to confirm the histological subtype, the burnt-out EMG pattern may simply reflect the prolonged delay, swallowing improvement was assessed clinically rather than by videofluoroscopy, and a broader myositis-specific antibody panel was not run. As a single case, the findings cannot be generalized to all populations. Still, the patient’s own account captures the stakes. She described years of declining function, sudden distress when swallowing failed, and relief at finally having a clear diagnosis after treatment restored her strength and her ability to eat normally. For clinicians, the message is blunt: autoimmune myopathy belongs on the differential for any longstanding unexplained proximal weakness, and the antibody that defines it is a simple blood test away.

Subject of Research: Anti-U1-RNP-positive inflammatory myopathy presenting with oropharyngeal dysphagia

Article Title: Anti‐U1‐RNP‐Positive Inflammatory Myopathy Presenting With Dysphagia: A Case Report

Article References: Anjlee, Rasheed, S., Ashfaq, M., Bai, S., Yaqubi, A. J., & Raza, A. A. (2026). Anti‐ U1 ‐ RNP ‐Positive Inflammatory Myopathy Presenting With Dysphagia: A Case Report. Clinical Case Reports, 14(10), Article e73676. https://doi.org/10.1002/ccr3.73676

Image Credits: AI Generated

DOI: 10.1002/ccr3.73676

Keywords: anti-U1-RNP antibodies, mixed connective tissue disease, inflammatory myopathy, dysphagia, myositis, creatine kinase, electromyography, methylprednisolone, autoimmune disease, anemia, rheumatology, case report

The central premise is deceptively simple: early ILD is usually subclinical, producing no symptoms while fibrosis and inflammation silently remodel the pulmonary interstitium. Patients, however, often present to dermatologists early in their disease course with rashes, skin thickening, nailfold changes, or ulcers that precede any respiratory complaint. Because radiographic evidence of ILD frequently appears before pulmonary symptoms develop, the dermatologist’s exam room may be the single best early-warning station for lung disease in this population. The authors argue that dermatologists who understand which skin phenotypes and autoantibody profiles signal elevated pulmonary risk can trigger imaging and referral years before a patient ever reports breathlessness.

The technical backbone of ILD evaluation rests on two pillars: pulmonary function testing (PFTs), including spirometry, lung volumes, and diffusing capacity for carbon monoxide (DLCO), and high-resolution computed tomography (HRCT). HRCT remains the diagnostic gold standard because it detects structural lung abnormalities—ground-glass opacities, reticulation, traction bronchiectasis, and honeycombing—before symptoms arise or before chest radiographs and PFTs become abnormal. Current guidelines broadly recommend against substituting PFTs for HRCT when ILD is suspected, a point underscored by data showing that PFTs alone carry a 62 percent false-negative rate at initial screening for systemic sclerosis-associated ILD. The predominant imaging pattern in most of these diseases is nonspecific interstitial pneumonia (NSIP), although usual interstitial pneumonia (UIP) predominates in systemic vasculitis.

Systemic sclerosis illustrates the stakes most vividly. Recent pooled estimates suggest ILD affects approximately 47 percent of patients with the disease, and lung disease—including pulmonary fibrosis—has now replaced renal crisis as the leading cause of scleroderma-related death. The review emphasizes that dermatologic phenotype is tightly linked to pulmonary risk: patients with diffuse cutaneous disease, in which skin thickening extends proximal to the elbows and knees or onto the trunk, face earlier-onset and more progressive ILD than those with limited cutaneous disease. Anti-topoisomerase I (anti-Scl-70) antibodies mark particularly high risk, while anticentromere antibodies, more typical of limited disease, generally predict lower ILD prevalence. Rarer autoantibodies refine the picture further: anti-Th/To is linked to pulmonary fibrosis and hypertension, anti-U11/U12 RNP to severe fibrosis and increased fibrosis-related mortality, anti-PM/Scl to a myositis-overlap phenotype with high pulmonary fibrosis prevalence, and anti-Ro52 to steeper declines in vital capacity over time.

Screening recommendations for systemic sclerosis are now firm. The American College of Rheumatology and the American College of Chest Physicians recommend that every patient with newly diagnosed disease undergo baseline HRCT and PFTs with DLCO, followed by PFTs every three to twelve months for the first three to five years and at least every six to twelve months thereafter. Short-term progression predicts mortality better than baseline severity, making longitudinal monitoring essential. The OMERACT consensus defines clinically meaningful progression as a relative decline in forced vital capacity of at least 10 percent over one year, or a 5 to 10 percent decline accompanied by a 15 percent or greater drop in DLCO—thresholds associated with increased mortality. Novel low-dose HRCT protocols have demonstrated 88 percent sensitivity and 91 percent accuracy in detecting scleroderma-ILD, and emerging data suggest transthoracic lung ultrasound could serve as a non-ionizing adjunct, though neither has yet replaced standard HRCT in guidelines.

The idiopathic inflammatory myopathies present an even more urgent dermatologic challenge. Myositis-specific autoantibodies (MSAs) powerfully predict organ involvement, and several flag severe pulmonary risk. In antisynthetase syndrome, defined by antibodies against aminoacyl-transfer RNA synthetases, as many as 89 percent of antibody-positive patients show some form of ILD, with anti-PL-7 and anti-PL-12 carriers faring worse than those with anti-Jo-1. Dermatomyositis adds its own red flags: the anti-MDA5 antibody, present in a subset of patients with clinically amyopathic dermatomyositis, is 86 percent specific and 77 percent sensitive for rapidly progressive ILD—a catastrophic subtype that worsens within a month despite high-dose corticosteroids, sends 40 to 60 percent of patients to intensive care, and carries a 45 to 51 percent hospital mortality rate. Painful palmar papules, cutaneous and oral ulceration, elevated ferritin, and lymphocytopenia may all predict this trajectory, and the review is unambiguous that such patients warrant urgent pulmonary evaluation.

The remaining conditions show a spectrum of risk. In systemic lupus erythematosus, ILD prevalence is comparatively low at 1 to 15 percent, and five-year mortality of 14.7 percent is better than in other autoimmune ILDs, but Raynaud’s phenomenon, sclerodactyly, and irregular nailfold capillaries can signal radiographic lung involvement—often reflecting overlap syndromes that must be excluded before attributing risk to lupus alone. Mixed connective tissue disease, defined by high-titer anti-U1 RNP antibodies, carries an ILD prevalence estimated at 34 to 66 percent, and even modest lung involvement on HRCT matters: ten-year survival fell from 87 percent in patients with less than 5 percent lung volume involvement to 60 percent in those with more than 10 percent. Nailfold capillaroscopy, showing enlarged capillaries and scleroderma-pattern changes, may help dermatologists identify MCTD patients who need closer pulmonary scrutiny.

Sjögren’s disease and systemic vasculitis round out the picture. A meta-analysis estimated ILD prevalence at roughly 23 percent in primary Sjögren’s, with cumulative incidence climbing to 20 percent within five years of diagnosis; anti-Ro52 positivity raised prevalence to 41.9 percent versus 16.2 percent in antibody-negative patients, and pooled five-year survival among affected patients was 82 percent. Guidelines from both ERS/EULAR and ACR/CHEST recommend risk-based screening with PFTs and HRCT for patients with features such as older age, male sex, Raynaud phenomenon, lymphopenia, and anti-Ro52 positivity, while explicitly rejecting chest radiography and six-minute walk testing as screening tools. In ANCA-associated vasculitis, ILD prevalence reaches as high as 45 percent in microscopic polyangiitis and 23 percent in granulomatosis with polyangiitis—high enough that ILD was added as a classification criterion for MPA in the 2022 ACR/EULAR guidelines. Notably, no major guideline yet defines evidence-based surveillance intervals for vasculitis-associated ILD, a gap the authors highlight as a priority for future research.

The review’s unifying message is that dermatologists occupy a uniquely powerful position in the multidisciplinary care of these patients. By pairing careful skin examination—recognizing Gottron’s papules, heliotrope rash, mechanic’s hands, shawl and V signs, sclerodactyly, calcinosis, and nailfold changes—with targeted autoantibody testing and a focused review of systems probing dyspnea, cough, and exercise intolerance, dermatologists can stratify risk long before respiratory symptoms emerge. Prompt rheumatology referral remains essential for confirming any suspected systemic autoimmune diagnosis, and pulmonary referral is triggered by symptoms, abnormal PFTs, or HRCT findings. As the authors conclude, familiarity with evidence-based screening and monitoring recommendations, and with the specific cutaneous signatures that demand them, is the key to reducing diagnostic delays and getting patients the antifibrotic and immunosuppressive therapies that increasingly can alter the course of autoimmune lung disease.

Subject of Research: Cutaneous manifestations as risk markers for interstitial lung disease in systemic autoimmune rheumatic diseases

Article Title: Cutaneous manifestations of systemic autoimmune rheumatic diseases including systemic sclerosis, idiopathic inflammatory myopathies, systemic lupus erythematous, mixed connective tissue disease, Sjögren’s disease, and systemic vasculitis and the association with interstitial lung disease: a review of dermatologic risk stratification, screening and monitoring guidelines, and indications for pulmonary referral

Article References: Kirven, R. M., Bogunovich, K., Feibel, A. B., Amigo, M., Trovato, S., Massick, S. C., Allen, J., Ajam, A., & Bechtel, M. A. (2026). Cutaneous manifestations of systemic autoimmune rheumatic diseases including systemic sclerosis, idiopathic inflammatory myopathies, systemic lupus erythematous, mixed connective tissue disease, Sjögren’s disease, and systemic vasculitis and the association with interstitial lung disease: a review of dermatologic risk stratification, screening and monitoring guidelines, and indications for pulmonary referral. Archives of Dermatological Research, 318(1), Article 467. https://doi.org/10.1007/s00403-026-04966-0

Image Credits: AI Generated

DOI: 10.1007/s00403-026-04966-0

Keywords: interstitial lung disease, systemic sclerosis, dermatomyositis, systemic lupus erythematosus, mixed connective tissue disease, Sjögren's disease, ANCA-associated vasculitis, autoantibodies, HRCT screening, pulmonary function testing, dermatology, autoimmune rheumatic disease